FTC on board with Bristol-Myers/Celgene tie-up on Otezla sale
The U.S. Federal Trade Commission (FTC) says Celgene’s (CELG) divestment of psoriasis med Otezla (apremilast) will settle its charges that its planned merger with Bristol-Myers Squibb (NYSE:BMY) would violate federal antitrust law.
About three months ago, the company announced that it had agreed to sell global rights to Amgen (NASDAQ:AMGN) for $13.4B in cash.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.